Medical Reserch and Education ›› 2018, Vol. 35 ›› Issue (3): 30-34.DOI: 10.3969/j.issn.1674-490X.2018.03.005

Previous Articles     Next Articles

  

  • Received:2017-12-21 Online:2018-06-25 Published:2018-06-25

Abstract: Objective To evaluate the effects of Shugan Granule on cerebral infarction followed depression. Methods 80 patients with cerebral infarction followed depression were randomly divided into two groups by mechanical sampling. 40 cases of the treatment group were treated with psychological intervention and combined with orally Shugan Granule 1 bag/time, 2 times a day. 40cases of the control group were only given psychological intervention. The treatment time was 60 d. The treatment effects were assessed using Hamilton anxiety scale(HAMD)before and after treatment at the 60 th day. Results The treatment group's effective rate of the and the control group's effective rate were respectively 85.0%(34/40)and 30.0%(12/40), the difference was statistically significant between the two groups(P<0.05). The HAMD score before treatment showed no significant difference between the two groups[(28.10±3.42)vs(27.50±2.30)](P>0.05), the score of the treatment group after treatment at days 60 was(6.35±3.05), compared with prior treatment has statistically significant(P<0.05), the score of the control group after treatment at days 60 was(13.01±3.01), compared with prior treatment has statistically significant(P<0.05), which indicated that there was statistically significant between the treatment group after treatment at 60th day and the control group(P<0.05). The levels of tumor necrosis factor-α(TNF-α)and C-reactive protein(CRP)in the treatment group decreased significantly than that in the controls(P<0.05). Neither group had significant adverse reactions. Conclusion Shugan Granule has positive treatment effects in patients with cerebral infarction followed depression. There are fewer adverse reactions, so there are high security in clinical applications.

Key words: cerebral infarction, depression, psychotherapy, Shugan Granule, tumor necrosis factor-α, C-reactive protein

CLC Number: